Bufalin dry powder inhalant as well as preparation method and application thereof

A technology of dry powder inhaler and dry powder inhaler, applied in the field of dry powder inhaler, can solve the problems such as no bufalin dry powder inhaler, and achieve the effects of avoiding first-pass effect, overcoming slow onset of effect, and high patient compliance

Active Publication Date: 2011-11-23
JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
View PDF11 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Currently there is no research report on bufalin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] Preparation of inhalation: bufolin was pulverized to D 90 = Below 4 microns, mix with lactose with a particle size of 45-90 microns in a mass ratio of 1:9, pack the drug powder into capsules or blisters or dry powder inhalers to obtain inhalers.

Embodiment 2

[0025] Preparation of inhalation: bufolin was pulverized to D 90 = 4 microns, mixed with lactose with a particle size of 45-90 microns and leucine with a particle size of 45-65 microns in a ratio of 10:90:1, packed into capsules or blisters or dry powder inhalers, to obtain inhalant.

Embodiment 3

[0027] Preparation of inhalation: bufolin was pulverized to D 90 = 4 microns, mixed with leucine with a particle size of 45-120 microns at a ratio of 1:9, packed into capsules or blisters or dry powder inhalers to obtain an inhaler.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Particle sizeaaaaaaaaaa
Login to view more

Abstract

The invention relates to a dry powder inhalant, in particular to a Bufalin dry powder inhalant, the preparation method of the dry powder inhalant and the application in preparing drug for treating lung tumors. The Bufalin dry powder inhalant is characterized in that the Bufalin dry powder inhalant is composed of Bufalin and pharmaceutically acceptable auxiliary materials, wherein the mass ratio of the Bufalin to pharmaceutically acceptable auxiliary materials is (1:0.01)-(1:110). The dry powder inhalant by taking the Bufalin as the main drug can directly act on an affected part by aiming at the lung tumor to lower the possibility of toxic and side effect and improve the bioavailability. According to the Bufalin dry powder inhalant, the defects that the oral-administration preparation slowly takes effect, the preparation has low bioavailability and the like can be overcome, and the problems of low Bufalin content, inconvenient use, poor patient complicance and the like in the injectioncan be solved. Thus, the Bufalin is prepared into the dry powder inhalant, which has great prospect for developing new drug.

Description

Technical field: [0001] The invention relates to a dry powder inhaler, specifically a dry powder inhaler made of bufalin, a preparation method of the dry powder inhaler and an application in the preparation of a drug for treating lung tumors. Background technique: [0002] Toad poison is the main active ingredient in toad venom. It belongs to cardiac glycosides, white crystals, fat-soluble substances, and its molecular formula is: C 24 h 34 o 4 , has pharmacological effects such as anti-tumor, analgesic and cardiotonic, anti-inflammatory and immune-enhancing. At present, injections, oral liquids, and tablets containing bufalin have been used clinically, and have good curative effects on liver cancer, lung cancer, gastric cancer, etc. Anti-tumor tests in vitro have shown that the tumor inhibition rate of preparations containing bufalin is 26.3-69% %. Injections are mainly composed of water-soluble ingredients, and the content of bufalin is extremely low, and the injection...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/72A61K9/14A61K31/585A61K47/26A61P35/00A61P11/00
Inventor 陈彦贾晓斌张振海刘璇周蕾
Owner JIANGSU PROVINCE INST OF TRADITIONAL CHINESE MEDICINE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap